目的：观察更昔洛韦眼用凝胶联合脾氨肽口服冻干粉治疗上皮型单纯疱疹病毒性角膜炎(HSK)的效果。

方法：选取2015-01/2016-06在我院眼科门诊确诊的70例70眼HSK患者，随机分为对照组和试验组。两组患者均采用更昔洛韦眼用凝胶治疗，试验组在此基础上口服脾氨肽冻干粉。两组患者连续用药30d。比较两组患者的临床治愈率、角膜溃疡愈合时间、疼痛减轻时间、畏光消失时间、视力改善情况及复发率等。

结果：治疗30d后，试验组患者临床治愈率(80%)显著高于对照组(51%)，差异有统计学意义(P<0.05)。与对照组相比，试验组患者角膜溃疡愈合时间、疼痛缓解时间及畏光消失时间均缩短，差异均有统计学意义(P<0.05)。随访1a，试验组患者复发率为14%，对照组为67%，试验组复发率低于对照组，差异有统计学意义(P<0.05)。

结论：更昔洛韦眼用凝胶联合脾氨肽口服冻干粉治疗上皮型HSK疗效好，能显著提高视力及临床治愈率，缩短病程，降低复发率。

METHODS: Totally 70 cases(70 eyes)with HSK diagnosed in Ophthalmology Department of our hospital from January 2015 to June 2016 were enrolled. All the patients were divided into control group and experimental group randomly. Control group was treated by ganciclovir eye gel, 6 times per day; while experimental group was treated by ganciclovir eye gel combined with spleen ammonia peptide oral freeze-dried powder, administered by cool white boiling water at daily bedtime, 2 milligram of every time. All patients were treated for 30d. Then the therapeutic effects of two groups, including the cure rate, time of corneal ulcer healing, pain relief, photophobia disappeared, vision improvement and recurrence rate were compared and analyzed.

RESULTS: The therapeutic effects of experimental group was better than the control group. The cure rate was 80% for experimental group and 51% for control group. The clinical cure rate in experimental group was significantly higher than that of the control group(P<0.05). The time for corneal ulcer healing and pain relief and photophobia disappeared in experimental group was significantly shorter than that for the control group(P<0.05). The recurrence rate in the 1-year follow-up was 14% for experimental group and 67% for control group. The clinical recurrence rate in experimental group was significantly lower than that of the control group(P<0.05).

CONCLUSION: The application of ganciclovir eye gel combined with spleen ammonia peptide oral freeze-dried powder in epithelial herpes simplex keratitis, which improves visual acuity, the cure rate and shortens the course of disease and reduces the recurrence rate, is the ideal treatment of epithelial herpes simplex keratitis at present.